Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis

Features of MOG required for recognition by patients with MOG antibody-associated disorders

(2021) Caterina Macrini et al.   BRAIN

Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder

(2021) Tetsuya Akaishi et al.   NEUROLOGY

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

(2021) James F Howard et al.   LANCET NEUROLOGY

Myelin-oligodendrocyte glycoprotein antibody-associated disease

(2021) Romain Marignier et al.   LANCET NEUROLOGY

Anti‐neonatal Fc receptor (FcRn) antibody treatment ameliorates experimental epidermolysis bullosa acquisita in mice

(2020) Anika Kasprick et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

(2020) Anthony Traboulsee et al.   LANCET NEUROLOGY

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder

(2020) John J. Chen et al.   NEUROLOGY

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort

(2020) Krenar Veselaj et al.   CNS Neuroscience & Therapeutics

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients

(2020) Daniel H Whittam et al.   Multiple Sclerosis and Related Disorders

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

(2020) Tadeusz Robak et al.   Blood Advances

Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis

(2020) Vera Bril et al.   NEUROLOGY

Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease

(2020) Wei Sun et al.   MOLECULAR THERAPY

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis

(2019) Robert Hoepner et al.   ACTA NEUROPATHOLOGICA

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

(2019) Sean J. Pittock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis

(2019) Praveena Manogaran et al.   Acta Neuropathologica Communications

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

(2019) Bruce A C Cree et al.   LANCET

Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis

(2019) Andrés Cruz-Herranz et al.   Journal of Neuroinflammation

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

(2019) Takashi Yamamura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

(2019) Adrian C. Newland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein

(2018) Melania Spadaro et al.   ANNALS OF NEUROLOGY

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

(2018) S. Jarius et al.   Journal of Neuroinflammation

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

(2018) Giordani Rodrigues dos Passos et al.   Frontiers in Neurology

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

(2018) Bryan Smith et al.   mAbs

Reliable detection of low visual acuity in mice with pattern visually evoked potentials

(2018) Naoyuki Tokashiki et al.   Scientific Reports

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study

(2018) Leona E. Ling et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia

(2018) Bryan Smith et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients

(2017) Shahd H. M. Hamid et al.   JOURNAL OF NEUROLOGY

Comparison of optomotor and optokinetic reflexes in mice

(2017) Friedrich Kretschmer et al.   JOURNAL OF NEUROPHYSIOLOGY

Laquinimod enhances central nervous system barrier functions

(2017) Fred Lühder et al.   NEUROBIOLOGY OF DISEASE

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

(2017) Peter Kiessling et al.   Science Translational Medicine

Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes

(2016) Maria Sepúlveda et al.   JOURNAL OF NEUROLOGY

Intravenous immunoglobulin in neurology—mode of action and clinical efficacy

(2015) Jan D. Lünemann et al.   Nature Reviews Neurology

From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development

(2014) Avraham Ben-Nun et al.   JOURNAL OF AUTOIMMUNITY

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies

(2014) Joanna Kitley et al.   JAMA Neurology

The Role of FcRn in Antigen Presentation

(2014) Kristi Baker et al.   Frontiers in Immunology

Characterizing visual performance in mice: An objective and automated system based on the optokinetic reflex.

(2013) Boris Benkner et al.   BEHAVIORAL NEUROSCIENCE

Inflammatory demyelination induces glia alterations and ganglion cell loss in the retina of an experimental autoimmune encephalomyelitis model

(2013) Lioba Horstmann et al.   Journal of Neuroinflammation

Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis

(2013) Dilip K. Challa et al.   mAbs

Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model

(2011) D. A. Patel et al.   JOURNAL OF IMMUNOLOGY